Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations.

Front Pharmacol · 2020 · PMC7019112 · PMID 32116703

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the multivariate model at 16 weeks of cART, there was some indication that males had lower efavirenz concentrations (mean difference log efavirenz: −0.24; 95% CI: −0.49–0.02; p = 0.07), but results did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.